(Health-NewsWire.Net, July 22, 2017 ) Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema) discoloration and darkening of skin around the ulcer (known as hemosiderosis) hardened skin around the ulcer which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis) small smooth areas of white skin which may have tiny red spots (known as atrophie blanche) .
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical and Unknown stages are 3 7 1 5 and 2 respectively.
Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology) . - The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities. - The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology)
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles CardioVascular BioTherapeutics Inc CytoTools AG Daval International Ltd Factor Therapeutics Ltd FirstString Research Inc GangaGen Inc Hypo-Stream Ltd Leap Therapeutics Inc MediWound Ltd NovaLead Pharma Pvt Ltd Promore Pharma RegeneRx Biopharmaceuticals Inc RMB-Research GmbH Stratatech Corp
List of Tables Number of Products under Development for Venous Leg Ulcers (Crural ulcer) H2 2017 Number of Products under Development by Companies H2 2017 Products under Development by Companies H2 2017 Number of Products by Stage and Target H2 2017 Number of Products by Stage and Mechanism of Action H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by CardioVascular BioTherapeutics Inc H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by CytoTools AG H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by Daval International Ltd H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by Factor Therapeutics Ltd H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by FirstString Research Inc H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by GangaGen Inc H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by Hypo-Stream Ltd H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by Leap Therapeutics Inc H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by MediWound Ltd H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by NovaLead Pharma Pvt Ltd H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by Promore Pharma H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by RegeneRx Biopharmaceuticals Inc H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by RMB-Research GmbH H2 2017 Venous Leg Ulcers (Crural ulcer)-Pipeline by Stratatech Corp H2 2017 Venous Leg Ulcers (Crural ulcer)-Dormant Projects H2 2017 Venous Leg Ulcers (Crural ulcer)-Discontinued Products H2 2017